Urinary incontinence (UI), a prevalent condition affecting
|
|
- Leo Jacobs
- 6 years ago
- Views:
Transcription
1 JOURNAL OF GYNECOLOGIC SURGERY Volume 29, Number 5, 2013 ª Mary Ann Liebert, Inc. DOI: /gyn Tension-Free Vaginal Tape Plus Intradetrusor BOTOX â Injection Versus Tension-Free Vaginal Tape Versus Intradetrusor BOTOX Injection in Equal-Weight Mixed Urinary Incontinence: A Prospective Randomized Study Maliheh Keshvari Shirvan, MD, 1 Seyed Ali Seyedi Noughabi, MD, 1 and Hamid Reza Rahimi, MD, PhD(cand) 1 Abstract Objective: The aim of this study was to determine the safety of the placement of tension-free vaginal tape (TVT) plus intradetrusor BOTOX Ò (onabotulinumtoxina; Allergan, Inc., headquartered in Irvine, CA) injection, and the outcome after 12 months. Design: An open, prospective study was conducted on 93 patients presenting with stress and urgency urinary incontinence of the same severity from the patients point of view. Materials and Methods: Subjects were divided into three groups: TVT + intradetrusor BOTOX injection (group 1); TVT only (group 2); or BOTOX injection only (group 3). At baseline, and at 1, 6, and 12 months, each patient was assessed by taking a medical history and performing a physical examination, including a cough test, a Q-Tip test, a 1-hour pad test, upper urinary tract sonography, postvoid residue, urinary analysis and culture, serum chemistry; and scores on the International Constellation on Incontinence Questionnaire (ICIQ) Urinary Incontinence (UI), the ICIQ Overactive Bladder (OAB), and the ICIQ Quality of Life (QOL) instruments. Urodynamic studies, including filling cystometry, uroflowmetry, and abdominal leak-point pressure at baseline were performed. At a 1-month follow-up, cystometry and uroflowmetry were performed. Data were then analyzed using SPSS, Pearson s v 2, and Mann Whitney U test. Results: The overall ICIQ-UI scores in group 1 declined from 15.4 to 2.5, 0, and 0, in 1, 6, and 12 months, respectively. In addition, ICIQ-OAB scores improved from an original mean baseline of 10.1 to 2.6, 0, and 1.1, in 1, 6, and 12 months, respectively. There was a significant improvement in urinary continence and, therefore, QOL for group 1 patients ( p < 0.05). ICIQ-UI and ICIQ-OAB scores showed remarkable improvement in patients who underwent the sling procedure (group 2) and the BOTOX injection (group 3), respectively ( p < 0.05). Nevertheless, the reverse did not occur. (There was insignificant change in ICIQ-OAB in group 2 and in ICIQ-UI in group 3). Retention occurred in 2, 0, and 2 patients in groups 1, 2, and 3, respectively, with no significant difference. Upper urinary-tract ultrasonography, urinary analysis and culture, and serum chemistry were normal in all patients. Conclusions: TVT plus intradetrusor BOTOX injection is a feasible and safe procedure. The results showed that there were subjects cured or with marked improvement at a 12-month followup. ( J GYNECOL SURG 29:235) Introduction Urinary incontinence (UI), a prevalent condition affecting almost 40% of women, is categorized into the three most common types: stress urinary incontinence (SUI), urge urinary incontinence (UUI), and mixed urinary incontinence (MUI). 1 3 The latter involves involuntary leakage in relation to urgency, exertion, sneezing, or coughing, 4 with a prevalence rate of 11% 61% (mean = 29%). 5,6 Management for these types of UI differ; MUI has both stress and urgency components, requiring that particular attention be given to the dominant component on presentation, 7 whereas SUI and UUI treatment primary includes behavioral modification as well as pelvic-floor training (PFMT). 8,9 1 Department of Urology, Imam Reza Academic Hospital, and 2 Student Research Committee, Modern Sciences & Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 235
2 236 SHIRVAN ET AL. Medical therapy has been shown to be of limited value in SUI. Some other treatments have been suggested, such as cell therapy, and injection of peripheral blood total nucleated cells (TNCs) and platelets is a safe and effective treatment for SUI. 10 Therefore, tension-free vaginal tape (TVT) would be the first choice for treating SUI Patients with UUI, however, do need anticholinergic drugs to regain bladder function control 7 ; nevertheless, adverse side-effects namely dry mouth, constipation, and nausea may restrict the drugs therapeutic value, ultimately leading to discontinuation. 14 The efficacy and safety of the TVT procedure in preventing postoperative SUI were studied by Groutz et al. in 2004, and the procedure showed good results. 15 Cheng and Liu found that a TVT-obturator, a novel midurethral sling, was a safe and effective procedure for treating female SUI after 5 years of follow-up in a series of patients. 16 In 2001, a case was reported of a patient with genuine SUI, who was treated successfully by TVT and had a term pregnancy and a successful vaginal delivery 17 ; TVT is considered worldwide to be an acceptable, simple, effective, and minimally invasive surgical procedure. BTXA Ô (botulinum toxin type A; Hugh Source International Ltd., Tsim Sha Tsui East, Kowloon, Hong Kong) has become popular for managing detrusor overactivity in individuals with spinal-cord injury. 6,18 Because of this product s lowering effect on detrusor-generated pressure, the product can also be used to treat idiopathic detrusor overactivity, thus reducing the need for anticholinergic medication, as well as improving continence. 19,20 Another assumption is that this product helps decrease the urgency via reducing the number of sensory receptors across the bladder epithelium. 21,22 Repeat injections with BTXA are effective, and have been shown to reduce overactive bladder symptoms in a study by Grosse et al. 23 Usually, treatment for MUI depends upon determining the dominant component, 7 but the current study was intended to investigate the efficacy of a new modality of treatment a combination of BotoxÒ (onabotulinumtoxina; Allergan, Inc., headquartered in Irvine, CA), a similar product to BTXA, and suburethral sling procedure, in MUI patients, with both urge and stress components of equal weight. Materials and Methods Patients were selected who had the diagnosis of MUI, with the two components of the condition perceived as being of equal severity from the patients point of view. These patients were recruited from female patients who were referred to the Imam-Reza and Om-Al-Banin clinics between 2009 and 2011, in blocks of 6 patients each. In addition to PFMT for SUI, these patients had been given oxybutynin (20 30 mg daily) and tolterodine (4 mg daily) for UUI before the study. Inclusion criteria were patients who had both SUI and UUI of the same severity that were resistant to conservative treatments, or who had SUI and UUI of the same severity and had side-effects from medications used as treatment. Exclusion criteria were patients with known vesicoureteral reflux, vaginal prolapse beyond the introitus, or other significant pelvic-floor abnormalities with high pressure instability; neuromuscular disorders (e.g., muscular dystrophy, multiple sclerosis); or uncontrolled diabetes; patients who were pregnant or lactating or who planned to become pregnant during course of the study; patients with morbid obesity (defined as a body mass index 40) who were, therefore, not expected to benefit from treatment; and patients with current or acute conditions involving cystitis or urethritis, a history of urogenital cancer, or a physical or mental disability. Ninety-three patients with MUI were selected for this prospective randomized study. The study was conducted in accordance with the 1996 version of principles of Declaration of Helsinki and with Good Clinical Practice standards. The study protocol, informed consent form, and the other study-related documents were reviewed and approved by the human research ethics committee of the Mashhad University of Medical Sciences. All patients were able to read and understand, and were willing to sign the informed consent form for the study. The severity of the kind of incontinence (UUI or SUI) from the patients point of view was equal in all patients. Ninety-three subjects were divided into three groups and randomization was performed on them; group 1 received TVT and BOTOX, Ò whereas the other two groups were given TVT or BOTOX (groups 2 and 3, respectively). For each patient, an upper urinary-tract scan, postvoid residue, and a 1-hour pad test were performed after taking a history and conducting a physical examination including a cough test and a Q-Tip test. Urine analysis, urine culturing, and serum chemistry were also performed. No residual volume was determined in all patients. Subjective symptoms and quality of life were evaluated using a validated disease-specific questionnaire the International Consultation on Incontinence Questionnaire Urinary Incontinence (ICIQ-UI) and quality of life (ICIQ-QOL), which were translated into the patients local language. The ICIQ-UI was calculated at baseline and repeated at 1, 6, and 12 months after treatment. A higher score on the ICIQ-UI and the ICIQ-QOL indicated an unfavorable and a favorable condition, respectively. In addition, a urodynamic study including filling cystometry in a prone position, uroflowmetry (UFL), and abdominal leak-point pressure (ALPP) were conducted. In patients with ALPP < 90 cm H 2 O, a urethral pressure profile (UPP) test was performed. Any urinary iodine concentration (UIC) or increase in intravesical pressure > 20 cm H 2 O was defined as detrusor overactivity. In group 1, the subjects were subsequently injected with BOTOX (DysportÒ [Medicis; Scottsdale, AZ] total dose 250 U), which was diluted in 30 cc of normal saline, under general anesthesia via cystoscope at 30 intradetrusor sites; 1 cc was injected into each site (as first delineated by Schurch et al. 24 ), avoiding the trigone. The TVT (Gynecare TVT, Ethicon Inc., Somerville, NJ) was placed by a well-trained surgeon, with the patient under general or spinal anaesthesia, after which a cystoscopic check was performed to ensure that no bladder trauma had occurred during the procedure, and also to inspect the new position of the proximal urethra. In group 2 the TVT was placed, and in group 3, and BOTOX injections were given to using the same method as was used for group 1. The following day, a urethral catheter that had been placed in each study patient was removed while the patients were still receiving first-generation cephalosporin, which was continued for 1 week postoperatively. Clean intermittent self-catheterization was taught to patients who had urinary retention. The patients in group 1 were not given any antimuscarinic drugs for the following year, during which they were followed (at months 1, 6, and 12); but, in groups 2 and 3, the medications and PFMT were continued, respectively.
3 Table 1. The Data of Group 1 (TVT + BOTOX Ò Injection), Group 2 (TVT), and Group 3 (BOTOX Injection) Variables Mean SD (or number and %) Group 1 (n = 31) Group 2 (n = 31) Group 3 (n = 31) Total (n = 93) p-value Age 58/4 9 61/4 8/5 61/5 9/2 60/4 8/9 0/302 4/6 2/00 3/8 2/2 3/6 2/2 4 2/2 0/164 Number of successful pregnancies Menopause 25 (80/6%) 29 (87/9%) 35 (86/2%) 79 (84/9%) 0/702 MDP 23/5 4/1 23/7 3/5 23/5 3/5 23/6 3/7 0/977 MDC 269/7 52/3 273/7 49/8 279/3 62/2 274/1 54/3 0/794 Pad Test Before operation (mean SD) 37/88 12/57 37/36 13/72 38/97 12/88 37/94 12/96 0/876* Number of pads user (%) 31 (100%) 31 (100%) 31 (100%) 93 (100%) 1st month F/U Number of pads user (%) 0 (0%) 9 (29%) 19 (61%) 28 (30/1%) < { 6th month F/U Number of pads user (%) 0 (0%) 9 (29%) 19 (61%) 28 (30/1%) < {{ 12th month F/U Number of pads user (%) 0 (0%) 9 (29%) 19 (61%) 28 (30/1%) < # ICIQ-UI Before operation 15/4 2 14/9 2/2 14/2 1/7 14/86 2/09 0/079* 1st month F/U 2/8 1/6 7/3 1/ /89 3/96 < 0.05 { 6th month F/U 0 6/6 1/4 10 1/1 5/49 4/2 < 0.05 {{ 12th month F/U 0 6/9 0/8 13/1 1/1 6/56 5/37 < 0.05 # ICIQ-QOL Before operation 34/8 4/6 34/9 4/2 34/9 4/2 68/27 10/00 0/577* 1st month F/U 79/4 10/8 47/9 4/4 40/7 2/7 43/35 12/86 < 0.05 { 6th month F/U 100/3 3/6 53/1 4/3 41/9 2/2 39/80 15/43 < 0.05 {{ 12th month F/U 102 3/2 53/2 4/3 37/3 3/1 43/27 15/68 < 0.05 # ICIQ-OAB Before operation 10/1 2/3 9/7 2/6 9/5 2/4 9/81 2/49 0/656* 1st month F/U 2/6 2 5/7 1/5 3/2 1/7 3/92 2/25 < 0.05 { 6th month F/U 0 7/1 1/5 0/5 0/7 2/7 3/4 < 0.05 {{ 12th month F/U 1/1 0/9 7/9 1/9 2/4 0/7 3/97 3/27 < 0.05 # PVR Less than 20 cc 26 (83/9%) 31 (100%) 24 (82/8%) 81 (87/09%) > 0.05 PVR 3 (9/7%) 0% 3 (10/3%) 6 (6/45%) Retention 2 (6/5%) 0% 2 (6/9%) 4 (4/30%) *Among groups before treatment; { among groups at 1st month of follow-up (F/U); {{ among groups 6th month of F/U; # among groups 12th month of F/U. Shaded areas indicate statistical significance. Botox Ò (onabotulinumtoxina; Allergan, Inc., headquartered in Irvine, CA): Brand used was Dysport Ò (Medicis; Scottsdale, AZ). TVT, tension-free vaginal tape; SD, standard deviation; MDP, mean detrusor pressure; MDC, mean detrusor capacity; ICIQ, International Constellation on Incontinence Questionnaire; UI, Urinary Incontinence; ICIQ-QOL, Quality of Life; ICIQ-OAB, Overactive Bladder; PVR, postvoiding residue. 237
4 238 SHIRVAN ET AL. Follow-up included taking a medical history, and conducting a physical examination, including a cough test, administering the ICIQ questionnaires, checking postvoid residual volume, and performing an upper urinary-tract scan. Cystometry and UFL were performed at the 3-month follow-up. The collated data were then statistically analyzed using Pearson s v 2 Student s t-test (paired) and a Mann Whitney U test to process categorical and continuous variables, respectively. Data analysis and storage were performed with SPSS 11.0, using a p-value of 0.05 to define significance. Results were presented as the mean unless otherwise indicated. The Kolmogorov-Smirnov test was used for quantitative analysis of variables, normal distribution, whereas analysis of variance (ANOVA) and Tukey post-hoc tests were used to measure changes in groups with respect to original baseline levels in months 1, 6, and 12. Comparative analysis was subsequently performed at 1, 6, and 12 months, using a repeatedmeasures ANOVA, whereas j 2 tests were the statistical means in qualitative measurements. Results There was no exclusion among the 93 subjects, whose demographic data and baseline measurements are summarized in Table 1. As shown in Table 1, there was no significant difference in terms of demographic characteristics or ICIQ scores and baseline urodynamic variables among the groups. ALPP in 2 patients in group 1 was < 60 cm H 2 O, and UPP in both of groups showed intrinsic sphincter deficiency (ISD); the algorithm of the treatment was the same. Figures 1 3 depict the ANOVA repeated measures for ICIQ scores obtained at follow-up visits. The overall ICIQ-UI (Fig.1) scores in group 1 declined from a baseline median of 15.4 to 2.5, 0, and 0, at 1, 6, and 12 month follow-ups, respectively. (No subject needed to wear a pad following treatment). In addition, the relevant detrusor overactivity component score (ICIQ-Overactive Bladder [OAB]) improved, from an original mean baseline of 10.1 to 2.6, 0, and 1.1 at 1, 6, and 12 months, FIG. 2. International Consultation on Incontinence Questionnaire Quality of Life (ICIQ-QOL) changes during study in each group. respectively (Fig. 3). As can be seen in Figure 2, there was a significant improvement in urinary continence and, therefore, QOL, for patients treated in group 1 ( p < 0.05). ICIQ-UI and ICIQ-OAB scores showed remarkable improvement in patients who underwent the sling procedure (group 2) or who had BOTOX injections (group 3), respectively ( p < 0.05). Nevertheless, the reverse did not occur (there was insignificant change in ICIQ-OAB in group 2 and in ICIQ-UI in group 3; Figs. 1 and 2). In the first month follow-up, retention occurred in 2, 0, and 2 patients in groups 1, 2, and 3, respectively, and there was no significant difference among the three groups according to v 2 ( p = 0102; j 2 = 6/589; seetable1). In addition, at the 6 and 12 month follow-ups, postvoiding residue (PVR) was < 20 cc in all patients. Upper urinary tract scan and UFL showed normal results in all patients. Abnormal cystometry (including any UIC or increase in intravesical pressure) was FIG. 1. International Consultation on Incontinence Questionnaire Urinary Incontinence (ICIQ-IU) changes during study in each group. FIG. 3. International Consultation on Incontinence Questionnaire Overactive Bladder (ICIQ-OAB) changes during study in each group.
5 TVT AND BTX-A IN SUI AND MUI 239 seen at at the 1-month follow-up in 6, 27, and 7 patients in groups 1, 2 and 3, respectively. No adverse operative and/or postoperative complications were reported. Thus, most of the subjects stopped taking anticholinergic medications throughout the entire follow-up time, except for patients in group 2; in that group, 27 patients needed anticholinergic medications after the procedure for some periods of time. Discussion MUI still remains an insurmountable clinical challenge under particular circumstances, requiring concurrent multimodal treatment. By and large, there is an inclination among clinicians to treat the SUI component, which is the most disturbing symptom, although it has the best response to treatment (surgery), whereas patients with predominant UUI receive medical treatment as well as PFMT. Nevertheless, there is still a lack of clarity regarding choice of treatment in patients with an equal proportion of, or at least nearly equally disturbing signs of, both stress and urge components of MUI. Conventionally, and despite the lack of clear guidance in this respect, the medical treatment for patients with MUI is still anticholinergics. 25 A recent Cochrane review of 13 trials of PFMT exercise found it of equal efficacy in both SUI and MUI patients. However, the multicenter Behavior Enhances Drug Reduction of Incontinence (BE-DRI) trial conducted by the Urinary Incontinence Treatment Network (UITN) confirmed the superiority of behavioral therapy, PFMT, and medication combined over unimodal medication therapy for reducing symptoms in patients with UUI. 26,27 Williams et al. failed to establish any link between floor therapies and UI reduction in patients with MUI, despite positive signs regarding pelvic-floor function. 28 BOTOX, first produced by Van Ermengem in 1897, 29 has been shown to inhibit the release of certain neurotransmitters, namely acetylcholine, adenosine triphosphate, and neuropeptides such as substance P, and also to downregulate the expression of purinergic and capsicin receptors on afferent neurons in the bladder. 30 This lends support to the assumption that BOTOX can ameliorate detrusor overactivity via both sensory and motor pathways, with the aim of reducing urinary symptoms as well as QOL. There are still doubts about whether or not BOTOX can have long-term adverse effects on detrusor activity; however, Haferkamp et al. observed no histopathologic changes 22 months following injection. 31 Another known restriction concerns the immune-mediated tolerance toward BTXA (as noted above, a similar product to BOTOX) following repeated application, which can be overcome by shifting to another product, BTXB, in case tolerance occurs. 32 The growing popularity of this mode of treatment, because of significant responses recorded, is still on the rise. Some studies have underlined the efficacy (up to 85%) of surgical treatment using a midurethral sling in patients with MUI. Interestingly, the subjective cure rates for patients with MUI tend to be lower than for patients with pure SUI, although this is not statistically significant. 33 In a study by Groutz et al. of 3 patients, short-term postoperative urinary retention and/or voiding difficulties occurred, and 1 patient underwent repeat surgery to adjust the sling. 34 In the current study, retention was seen in 4 patients (4.30% of total patients). The rate of onset of de novo irritative voiding after surgery ranges between 12% and 25.9%, for which a plausible explanation would be the use of PROLENE Ô tape use and local biologic alterations This problem is also often diagnosed late no sooner than 1 month postoperatively 35 and de novo urgency, seen in up to 26% of patients, is not as important when a combined regimen is used. Groutz et al. stated that the TVT operation is an invasive surgical procedure with excellent short- and medium-term objectivecurerates. 34 Failure of TVT occurs in > 10% of the operations; thus urogynecologists are faced with an unaddressed issue when performing or recommending such operations. 38 In the current study, ICIQ scores improved significantly at week 4 and afterward ( p > 0.001), indicating better continence. The drawback, however, was that it was impossible to blind the surgeons to the procedure. Conclusions Based on the short-term results in the current study, it is a safe assumption to claim that women with MUI have alternative treatment options. Given the high success rate of the combined procedure, as well as unreported morbidity and mortality, this procedure warrants further assessment, using larger samples studied for longer periods. Acknowledgments This research project was supported by the Mashhad University of Medical Science Research Council (project number: MUMS/89703). Disclosure Statement No competing financial interests exist. References 1. Chou EC, Blaivas JG, Chou LW, Flisser AJ, Panagopoulos G. Urodynamic characteristics of mixed urinary incontinence and idiopathic urge urinary incontinence. Neurourol Urodyn 2008;27: Hannestad YS, Rortveit G, Sandvik H, Hunskaar S. A community-based epidemiological survey of female urinary incontinence: The Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trondelag. J Clin Epidemiol 2000;53: Labrie J, van der Graaf Y, Buskens E, Tiersma SE, van der Vaart HC. Protocol for Physiotherapy Or TVT Randomised Efficacy Trial (PORTRET): A multicentre randomised controlled trial to assess the cost-effectiveness of the tension free vaginal tape versus pelvic floor muscle training in women with symptomatic moderate to severe stress urinary incontinence. BMC Womens Health 2009;9: Abrams P, Cardozo L, Fall M. The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Urology 2003;61: Hunskaar S, Burgio K. Epidemeology of urinary and faecal incontinence and pelvic organ prolapse. In: Abrams P, Cardozo L, Khoury S, eds. Incontinence. Paris: Health Publication, 2005: Patki P, Woodhouse JB, Patil K, Hamid R, Shah J. An effective day case treatment combination for refractory
6 240 SHIRVAN ET AL. neuropathic mixed incontinence. Int Braz J Urol 2008; 34: Staskin D, Te A. Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence. BJU Int 2006;97: Wein A. Pharmacologic options for the overactive bladder. Urology 1998;51: Elser D, Wyman J, McClish D. The effect of bladder training, pelvic floor muscle training, or combination training on urodynamic parameters in women with urinary incontinence. Neurourol Urodyn 1999;18: Shirvan MK, Alamdari DH, Mahboub MD, Ghanadi A, Rahimi HR, Seifalian AM. A novel cell therapy for stress urinary incontinence, short-term outcome. Neurourol Urodyn 2013;32: Doo C, Hong B, Chung B, Kim J, Jung HC, Lee KS, Choo MS. Five-year outcomes of the tension-free vaginal tape procedure for treatment of female stress urinary incontinence. Eur Urol 2006;50: Holmgren C, Nilsson S, Lanner L, Hellberg D. Long-term results with tension-free vaginal tape on mixed and stress urinary incontinence. Obstet Gynecol 2005;106: Kuuva N, Nilsson C. Long-term results of the tension-free vaginal tape operation in an unselected group of 129 stress incontinent women. Acta Obstet Gynecol Scand 2006;85: Ksibi I, Godard A-L, Azouvi P, Denys P, Dziri C. Botulinum toxin and refractory non-neurogenic overactive detrusor. Ann Phys Rehabil Med 2009;52: Groutz A, Gold R, Pauzner D, Lessing JB, Gordon D. Tension-free vaginal tape (TVT) for the treatment of occult stress urinary incontinence in women undergoing prolapse repair: A prospective study of 100 consecutive cases. Neurourol Urodyn 2004;23: Cheng D, Liu C. Tension-free vaginal tape-obturator in the treatment of stress urinary incontinence: A prospective study with five-year follow-up. Eur J Obstet Gynecol Reprod Biol 2012;161: Lo TS, Huang HJ, Tseng LH. Success of tension-free vaginal tape procedure after pregnancy and vaginal delivery. J Gynecol Surgery 2001;17: Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results. J Urol 2000;164: Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-a toxin. J Urol 2005;174: Patki P, Hamid R, Arumugam K, Shah P, Craggs M. Botulinum toxin-type A in the treatment of drug resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury. BJU Int 2006;98: Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB. Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology 2004;64: Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, Dasgupta P, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005;174: Grosse J, Kramer G, Stohrer M. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005;47: Schurch B, de Seze M, Denys P, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005;174: Hay-Smith J, Herbison P, Ellis G, Morris A. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2005:CD Burgio KL, Kraus SR, Menefee S, et al. Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial. Ann Intern Med 2008;149: Dumoulin C, Hay-Smith J. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev 2010:CD Williams KS, Assassa RP, Gillies CL, et al. A randomized controlled trial of the effectiveness of pelvic floor therapies for urodynamic stress and mixed incontinence. BJU Int 2006;98: Chapple C, Patel A. Botulinum toxin: New mechanisms, new therapeutic directions? Eur Urol 2006;49: van Ermengem E. Classics in infectious diseases: A new anaerobic bacillus and its relation to botulism. Rev Infect Dis 1979;1: Haferkamp A, Schurch B, Reitz A, et al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder. Eur Urol 2004;46: Ghei M, Maraj BH, Miller R, et al. Effects of botulinum toxin B on refractory detrusor overactivity: A randomized, doubleblind, placebo controlled, crossover trial. J Urol 2005;174: Jeffry L, Deval B, Birsan A, Soriano D, Darai E. Objective and subjective cure rates after tension-free vaginal tape for treatment of urinary incontinence. Urology 2001;58: Groutz A, Gordon D, Wolman I, Jaffa AJ, David MP, Lessing JB. Tension-free vaginal tape for stress urinary incontinence: Is there a learning curve? Neurourol Urodyn 2002;21: Jeffry L, Deval B, Birsan A, Soriano D, Darai E. Objective and subjective cure rates after tension-free vaginal tape for treatment of urinary incontinence. Urology 2001;58: Meschia M, Pifarotti P, Spennacchio M, Buonaguidi A, Gattei U, Somigliana E. A randomized comparison of tension-free vaginal tape and endopelvic fascia plication in women with genital prolapse and occult stress urinary incontinence. Am J Obstet Gynecol 2004;190: Carr LK, Webster GD. Voiding dysfunction following incontinence surgery: Diagnosis and treatment with retropubic or vaginal urethrolysis. J Urol 1997;157: Neuman M. Trans vaginal tape readjustment after unsuccessful tension-free vaginal tape operation. Neurourol Urodyn 2004;23:282. Address correspondence to: Maliheh Keshvari Shirvan, MD Department of Urology Imam Reza Academic Hospital Faculty of Medicine Mashhad University of Medical Sciences Imam Reza Hospital Emam Reza Square Ebne Sina Avenue P.O. Box Mashhad Iran KeshvariM@mums.ac.ir
Hospital and Tzu Chi University, Hualien, Taiwan
LUTS (2012) 4, 29 34 ORIGINAL ARTICLE Difficult Urination Does Not Affect the Successful Outcome after 100U OnabotulinumtoxinA Intravesical Injection in Patients with Idiopathic Detrusor Overactivity Yih-Chou
More informationObjectives. Prevalence of Urinary Incontinence URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS
URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS Lisa S Pair, MSN, CRNP Division of Urogynecology and Pelvic Reconstructive Surgery Department of Obstetrics and Gynecology University of Alabama
More informationAn Effective Day Case Treatment Combination for Refractory Neuropathic Mixed Incontinence
Neurourology A Day Case Treatment for Neuropathic Mixed Incontinence International Braz J Urol Vol. 34(1): 63-72, January - February, 2008 An Effective Day Case Treatment Combination for Refractory Neuropathic
More informationTreatment Outcomes of Tension-free Vaginal Tape Insertion
Are the Treatment Outcomes of Tension-free Vaginal Tape Insertion the Same for Patients with Stress Urinary Incontinence with or without Intrinsic Sphincter Deficiency? A Retrospective Study in Hong Kong
More informationResolution of urge urinary incontinence with midurethral sling surgery in patients with mixed incontinence and low-pressure urethra
Gynecol Surg (2012) 9:427 432 DOI 10.1007/s10397-012-0735-7 ORIGINAL ARTICLE Resolution of urge urinary incontinence with midurethral sling surgery in patients with mixed incontinence and low-pressure
More informationBotulinum Toxin: Applications in Urology
Botulinum Toxin: Applications in Urology Dr. Lee Jonat, PGY-4 Department of Urologic Sciences University of British Columbia Outline Mechanism of Action Technical Considerations Adverse Events Neurogenic
More informationO (P =.005) in the NDO group and from ± 9.92 cmh 2. O to ± cmh 2
MISCELLANEOUS Success Rate and Patients' Satisfaction Following Intradetrusor Dysport Injection in Patients with Detrusor Overactivity: A Comparative Study of Idiopathic and Neurogenic Types of Detrusor
More informationUrinary Incontinence for the Primary Care Provider
Urinary Incontinence for the Primary Care Provider Diana J Scott FNP-BC https://youtu.be/gmzaue1ojn4 1 Assessment of Urinary Incontinence Urge Stress Mixed Other overflow, postural, continuous, insensible,
More informationeuropean urology 52 (2007)
european urology 52 (2007) 1729 1735 available at www.sciencedirect.com journal homepage: www.europeanurology.com Neuro-urology Do Repeat Intradetrusor Botulinum Toxin Type A Injections Yield Valuable
More informationEfficacy of botulinum-a toxin in the treatment of detrusor overactivity incontinence: A prospective nonrandomized study
American Journal of Obstetrics and Gynecology (2005) 192, 1735 40 www.ajog.org Efficacy of botulinum-a toxin in the treatment of detrusor overactivity incontinence: A prospective nonrandomized study Matthias
More information2/9/2008. Men Women. Prevalence of OAB. Men: 16.0% Women: 16.9% Prevalence (%) < Age (years)
Definition Botox for Overactive Bladder Donna Y. Deng Assistant Professor UCSF Department of Urology Urinary urgency With or without urge incontinence Usually with frequency & nocturia International Continence
More informationURINARY INCONTINENCE. Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara
URINARY INCONTINENCE Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara Definition The involuntary loss of urine May denote a symptom, a sign or a condition Symptom the
More informationTension-free Vaginal Tape for Urodynamic Stress Incontinence
Long-term Results of Tension-free Vaginal Tape Insertion for Urodynamic Stress Incontinence in Chinese Women at Eight-year Follow-up: a Prospective Study YM CHAN MBBS, MRCOG, FHKAM (O&G), DCG, DCH, DFM,
More informationOveractive Bladder (OAB) and Quality of Life
Overactive Bladder (OAB) and Quality of Life Dr. Byron Wong MBBS (Sydney), FRCSEd, FRCSEd (Urol), FCSHK, FHKAM (Surgery) Specialist in Urology Central Urology Clinic Hong Kong Continence Society Annual
More informationOperative Approach to Stress Incontinence. Goals of presentation. Preoperative evaluation: Urodynamic Testing? Michelle Y. Morrill, M.D.
Operative Approach to Stress Incontinence Goals of presentation Michelle Y. Morrill, M.D. Director of Urogynecology The Permanente Medical Group Kaiser, San Francisco Review preoperative care & evaluation
More informationVarious Types. Ralph Boling, DO, FACOG
Various Types Ralph Boling, DO, FACOG The goal of this lecture is to increase assessment and treatment abilities for physicians managing urinary incontinence (UI) patients. 1. Effectively communicate with
More informationThe Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence
european urology supplements 5 (2006) 849 853 available at www.sciencedirect.com journal homepage: www.europeanurology.com The Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence Stefano
More informationPRE-OPERATIVE URODYNAMIC
PRE-OPERATIVE URODYNAMIC STUDIES: IS THERE VALUE IN PREDICTING POST-OPERATIVE STRESS URINARY INCONTINENCE IN WOMEN UNDERGOING PROLAPSE SURGERY? Dr K Janse van Rensburg Dr JA van Rensburg INTRODUCTION POP
More informationClinical Study Predictors of Response to Intradetrusor Botulinum Toxin-A Injections in Patients with Idiopathic Overactive Bladder
Advances in Urology Volume 2009, Article ID 328364, 4 pages doi:10.1155/2009/328364 Clinical Study Predictors of Response to Intradetrusor Botulinum Toxin-A Injections in Patients with Idiopathic Overactive
More informationUrinary Incontinence. Lora Keeling and Byron Neale
Urinary Incontinence Lora Keeling and Byron Neale Not life threatening. Introduction But can have a huge impact on quality of life. Two main types of urinary incontinence (UI). Stress UI leakage on effort,
More informationPredictors of Postoperative Voiding Dysfunction following Transobsturator Sling Procedures in Patients with Stress Urinary Incontinence
Voiding Dysfunction INJ 2010;14:26-33 Predictors of Postoperative Voiding Dysfunction following Transobsturator Sling Procedures in Patients with Stress Urinary Incontinence Sung-Tae Cho, Hyeong-Cheol
More informationUrodynamic findings in women with insensible incontinence
bs_bs_banner International Journal of Urology (2013) 20, 429 433 doi: 10.1111/j.1442-2042.2012.03146.x Original Article: Clinical Investigation Urodynamic findings in women with insensible Benjamin M Brucker,
More informationImpact of the Midurethral Sling Procedure on Quality of Life in Women with Urinary Incontinence
www.kjurology.org DOI:10.4111/kju.2010.51.2.122 Voiding Dysfunction Impact of the Midurethral Sling Procedure on Quality of Life in Women with Urinary Incontinence Hwa Su Lim, Jong Min Kim, Phil Hyun Song,
More informationOveractive bladder symptoms after midurethral sling surgery in women: Risk factors and management
Received: 4 January 2017 Accepted: 2 May 2017 DOI: 10.1002/nau.23328 REVIEW ARTICLE Overactive bladder symptoms after midurethral sling surgery in women: Risk factors and management Tom Marcelissen Philip
More informationTools for Evaluation. Urodynamics Case Studies. Case 1. Evaluation. Case 1. Bladder Diary SUI 19/01/2018
Urodynamics Case Studies Christopher K. Payne, MD Vista Urology & Pelvic Pain Partners Emeritus Professor of Urology, Stanford University Tools for Evaluation Ears, Eyes, and Brain Bladder diary Stress
More informationSequential Assessment of Urodynamic Findings before and aftertension-free Vaginal Tape (TVT) Operation for Female Genuine Stress Incontinence
European Urology European Urology 45 (2004) 362 366 Sequential Assessment of Urodynamic Findings before and aftertension-free Vaginal Tape (TVT) Operation for Female Genuine Stress Incontinence Long-Yau
More informationDuloxetine in women awaiting surgery
DOI: 1.1111/j.1471-528.6.879.x www.blackwellpublishing.com/bjog Review article H Drutz Ontario Power Generation Building, Toronto, Ontario, Canada Correspondence: Prof. Dr H Drutz, Mount Sinai Hospital,
More informationLong-Term Outcome of the Tension-Free Vaginal Tape Procedure in Female Urinary Incontinence: A 6-Year Follow-Up
www.kjurology.org DOI:10.4111/kju.2010.51.6.409 Voiding Dysfunction Long-Term Outcome of the Tension-Free Vaginal Tape Procedure in Female Urinary Incontinence: A 6-Year Follow-Up Jun Hyung Lee, Min Chul
More informationPhiladelphia College of Osteopathic Medicine. Victoria J. Kopec Philadelphia College of Osteopathic Medicine,
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Does Treatment With OnabotulinumtoxinA
More informationHow to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxina
Reviews How to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxina Mikolaj Przydacz A F, Tomasz Golabek A,E,F, Piotr Chlosta A,E,F Department of Urology, Jagiellonian
More informationGOVINDARAJ N. RAJKUMAR, DOUGLAS R. SMALL, ABDUL W. MUSTAFA and GRAEME CONN Department of Urology, Southern General Hospital, Glasgow, UK
Original Article BTXA IN DETRUSOR FOR REFRACTORY IDIOPATHIC DOA RAJKUMAR et al. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of
More informationTuesday 24 June Poster Session 1: Voiding Dysfunction Chairmen: C. Chapple and L. Stewart
Tuesday 24 June 10.30 11.30 Poster Session 1: Voiding Dysfunction Chairmen: C. Chapple and L. Stewart P001 Can oral antibiotic prophylaxis reduce the rate of infection after conventional urodynamic studies?
More informationINJ. Original Article INTRODUCTION. Int Neurourol J 2010;14: doi: /inj pissn eissn
Original Article Int Neurourol J 21;14:267-271 pissn 293-4777 eissn 293-6931 International Neurourology Journal The Influence of Preoperative Bladder Outlet Obstruction on Continence and Satisfaction in
More informationProspective randomized trial of 100u vs 200u botox in the treatment of idiopathic overactive bladder
Original Article Prospective randomized trial of vs botox in the treatment of idiopathic overactive bladder Waleed AlTaweel, Alaa Mokhtar, Danny M. Rabah 1 King Faisal Specialist Hospital and Research
More informationManagement of Female Stress Incontinence
Management of Female Stress Incontinence Dr. Arvind Goyal Associate Professor (Urology& Renal Transplant) Dayanand Medical College & Hospital, Ludhiana, Punjab, India Stress Incontinence Involuntary loss
More informationINCONTINENCE. Continence and Pelvic Floor Rehabilitation TYPES OF INCONTINENCE STRESS INCONTINENCE STRESS INCONTINENCE STRESS INCONTINENCE 11/08/2015
INCONTINENCE Continence and Pelvic Floor Rehabilitation Dr Irmina Nahon PhD Pelvic Floor Physiotherapist www.nahonpfed.com.au Defined as the accidental and inappropriate passage of urine or faeces (ICI
More informationTREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH
TREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH CONTENTS Overactive bladder (OAB) Treatment of OAB Beta-3 adrenoceptor agonist (Betmiga ) - Panacea? LASER treatment - a flash in the pan or the
More informationNew approaches in the pharmacological treatment of stress urinary incontinence
International Journal of Gynecology and Obstetrics 86 Suppl. 1 (2004) S1 S5 New approaches in the pharmacological treatment of stress urinary incontinence Keywords: Stress urinary incontinence; Epidemiology;
More informationHasheminejad Kidney Center (HKC), Iran University of Medical Sciences (IUMS), Tehran, Iran
ORIGINAL ARTICLE Vol. 43 (6): 1122-1128, November - December, 2017 doi: 10.1590/S1677-5538.IBJU.2016.0622 Abobotulinum - a toxin injection in patients with refractory idiopathic detrusor overactivity:
More informationOveractive Bladder: Diagnosis and Approaches to Treatment
Overactive Bladder: Diagnosis and Approaches to Treatment A Hidden Condition* Many Many patients self-manage by voiding frequently, reducing fluid intake, and wearing pads Nearly Nearly two-thirds thirds
More informationNATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Urinary incontinence: the management of urinary incontinence in women
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE 1 Guideline title SCOPE Urinary incontinence: the management of urinary incontinence in women 1.1 Short title Urinary incontinence 2 Background a) The National
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Urinary incontinence in women: the management of urinary incontinence in women 1.1 Short title Urinary incontinence in women
More informationManagement of OAB. Lynsey McHugh. Consultant Urological Surgeon. Lancashire Teaching Hospitals
Management of OAB Lynsey McHugh Consultant Urological Surgeon Lancashire Teaching Hospitals Summary Physiology Epidemiology Definitions NICE guidelines Evaluation Conservative management Medical management
More informationUrethral pressure measurement in stress incontinence: does it help?
Int Urol Nephrol (2009) 41:491 495 DOI 10.1007/s11255-008-9506-9 UROLOGY - ORIGINAL PAPER Urethral pressure measurement in stress incontinence: does it help? Bassem S. Wadie Æ Ahmed S. El-Hefnawy Received:
More informationAnatomical and Functional Results of Pelvic Organ Prolapse Mesh Repair: A Prospective Study of 105 Cases
International Journal of Clinical Urology 2018; 2(1): 20-24 http://www.sciencepublishinggroup.com/j/ijcu doi: 10.11648/j.ijcu.20180201.14 Anatomical and Functional Results of Pelvic Organ Prolapse Mesh
More informationEfficacy and Adverse Effects of Monarc Versus Tension-free Vaginal Tape Obturator: a Retrospective One-year Follow-up Study
Efficacy and Adverse Effects of Monarc Versus Tension-free Vaginal Tape Obturator: a Retrospective One-year Follow-up Study Yvonne KY CHENG MBChB, MRCOG William WK TO MBBS, M Phil, FRCOG, FHKAM (O&G) HX
More informationBotulinum toxin-a for the treatment of overactive bladder: UK contributions
473096URO6210.1177/2051415812473096Journal of Clinical UrologySeth et al. 2013 Original Article Botulinum toxin-a for the treatment of overactive bladder: UK contributions Journal of Clinical Urology 6(2)
More informationKey Words: urinary incontinence, suburethral slings
Evaluation of Transobturator Tension-Free Vaginal Tapes in the Surgical Management of Mixed Urinary Incontinence: 3-Year Outcomes of a Randomized Controlled Trial Mohamed Abdel-Fattah,*, Laura R. Hopper
More informationUrogynecology in EDS. Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018
Urogynecology in EDS Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018 One in three like me Voiding Issues Frequency/Urgency Urinary Incontinence neurogenic bladder Neurologic supply
More informationREVIEW ARTICLE. Botulinum-A Toxin s efficacy in the treatment of idiopathic overactive bladder
76 REVIEW ARTICLE Botulinum-A Toxin s efficacy in the treatment of idiopathic overactive bladder Marius Alexandru Moga, 1 Simona Banciu, 2 Oana Dimienescu, 3 Nicusor-Florin Bigiu, 4 Ioan Scarneciu 5 Abstract
More informationOutcomes of Midurethral Slings in Women with Concomitant Preoperative Severe Lower Urinary Tract Voiding Symptoms
ORIGINAL RESEARCH The Ochsner Journal 15:223 227, 2015 Ó Academic Division of Ochsner Clinic Foundation Outcomes of Midurethral Slings in Women with Concomitant Preoperative Severe Lower Urinary Tract
More informationRisk Factors of Voiding Dysfunction and Patient Satisfaction After Tension-free Vaginal Tape Procedure
J Korean Med Sci 2005; 20: 1006-10 ISSN 1011-8934 Copyright The Korean Academy of Medical Sciences Risk Factors of Voiding Dysfunction and Patient Satisfaction After Tension-free Vaginal Tape Procedure
More informationUrodynamics in women. Aims of Urodynamics in women. Why do Urodynamics?
Urodynamics in women Chendrimada Madhu MD, MA, MRCOG Subspecialty Trainee in Urogynaecology Southmead Hospital 2013 Aims of Urodynamics in women n Confirmation of incontinence and its cause n Definition
More informationUrinary Aspects of Multiple Sclerosis chronic condition with innovative treatment strategies. Dr. Boris Friedman May 2, 2012 OBJECTIVES
Urinary Aspects of Multiple Sclerosis chronic condition with innovative treatment strategies Dr. Boris Friedman May 2, 2012 OBJECTIVES 1) Definition and classification of MS 2) Interventional radiology
More informationBladder dysfunction in ALD and AMN
Bladder dysfunction in ALD and AMN Sara Simeoni, MD Department of Uro-Neurology National Hospital for Neurology and Neurosurgery Queen Square, London 10:15 Dr Sara Simeoni- Bladder issues for AMN patients
More informationFive-Year Outcomes of the Tension-Free Vaginal Tape Procedure for Treatment of Female Stress Urinary Incontinence
european urology 50 (2006) 333 338 available at www.sciencedirect.com journal homepage: www.europeanurology.com Female Urology Incontinence Five-Year Outcomes of the Tension-Free Vaginal Tape Procedure
More informationDiagnosis and Treatment of Urinary Incontinence. Urinary Incontinence
Diagnosis and Treatment of Urinary Incontinence Leslee L. Subak, MD Professor Obstetrics, Gynecology & RS Epidemiology, Urology University of California, San Francisco Urinary Incontinence Common - 25%
More informationBotulinum Toxin Injection for OAB: Indications & Technique
Classification of LUTS Botulinum Toxin Injection for OAB: Indications & Technique Sherif Mourad, MD Professor of Urology, Ain Shams University General Secretary of International Continence President of
More informationKathleen C. Kobashi, MD, FACS Head, Section of Urology and Renal Transplantation Virginia Mason Medical Center, Seattle, WA
Kathleen C. Kobashi, MD, FACS Head, Section of Urology and Renal Transplantation Virginia Mason Medical Center, Seattle, WA Disclosures Advisory Board and/or Speaker Allergan Medtronic Astellas AUA Guidelines
More informationPREVENTING URINARY INCONTINENCE through PELVIC FLOOR REHABILITATION in DISABLED ELDERLY
PREVENTING URINARY INCONTINENCE through PELVIC FLOOR REHABILITATION in DISABLED ELDERLY Paolo DI BENEDETTO Lecturer, Tor Vergata University, Rome, Italy Former Director of Rehabilitation Department Institute
More informationInfluence of Obesity on Short-term Surgical Outcome of the Transobturator Tape Procedure in Patients with Stress Urinary Incontinence
Urinary Incontinence INJ 2010;14:13-19 Influence of Obesity on Short-term Surgical Outcome of the Transobturator Tape Procedure in Patients with Stress Urinary Incontinence Dong-Un Tchey, Won-Tae Kim,
More informationClinical Study Cough Test during Tension-Free Vaginal Tape Procedure in Preventing Postoperative Urinary Retention
Advances in Urology Volume 2013, Article ID 797854, 4 pages http://dx.doi.org/10.1155/2013/797854 Clinical Study Cough Test during Tension-Free Vaginal Tape Procedure in Preventing Postoperative Urinary
More informationOveractive Bladder Syndrome
Overactive Bladder Syndrome behavioural modifications to pharmacological and surgical treatments Dr Jos Jayarajan Urologist Austin Health, Eastern Health Warringal Private, Northpark Private, Epworth Overactive
More informationINTRAVESICAL INJECTION OF BOTULINUM TOXIN TYPE A: MANAGEMENT OF NEUROPATHIC BLADDER AND BOWEL DYSFUNCTION IN CHILDREN WITH MYELOMENINGOCELE
PEDIATRIC UROLOGY INTRAVESICAL INJECTION OF BOTULINUM TOXIN TYPE A: MANAGEMENT OF NEUROPATHIC BLADDER AND BOWEL DYSFUNCTION IN CHILDREN WITH MYELOMENINGOCELE ABDOL-MOHAMMAD KAJBAFZADEH, SHAHRAM MOOSAVI,
More informationAdverse Events of Intravesical Botulinum Toxin A Injections for Idiopathic Detrusor Overactivity: Risk Factors and Influence on Treatment Outcome
EUROPEAN UROLOGY 58 (2010) 919 926 available at www.sciencedirect.com journal homepage: www.europeanurology.com Incontinence Adverse Events of Intravesical Botulinum Toxin A Injections for Idiopathic Detrusor
More informationEffects of Combined Pelvic Floor Muscle Exercises in Patient with Urinary Incontinence
MACROJOURNALS The Journal of MacroTrends in Health and Medicine Effects of Combined Pelvic Floor Muscle Exercises in Patient with Urinary Incontinence Vjollca Ndreu*, Fatjona Kamberi*, Enkeleda Sinaj*,
More informationOutcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder
Outcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder Michael K. Flynn,* Cindy L. Amundsen, MaryAnn Perevich, Fan Liu and George D. Webster
More informationPosterior Tibial Nerve Stimulation for Treating Neurologic Bladder in Women: a Randomized Clinical Trial
ORIGINAL ARTICLE Posterior Tibial Nerve Stimulation for Treating Neurologic Bladder in Women: a Randomized Clinical Trial Tahereh Eftekhar 1, Nastaran Teimoory 1, Elahe Miri 1, Abolghasem Nikfallah 2,
More informationI-STOP TOMS Transobturator Male Sling
I-STOP TOMS Transobturator Male Sling The CL Medical I-STOP TOMS sling for male stress urinary incontinence was developed in France where it is widely used and is the market leader. It is constructed with
More informationIntraoperative Observation of the Degree and Pattern of Urine Leakage before Adjustment of the Mesh during a Transobturator Tape Procedure
Original Article www.cmj.ac.kr Intraoperative Observation of the Degree and Pattern of Urine Leakage before Adjustment of the Mesh during a Transobturator Tape Procedure Jae-Joon Park, Hyung Ho Lee 1 and
More informationEUROPEAN UROLOGY 57 (2010)
EUROPEAN UROLOGY 57 (2010) 891 896 available at www.sciencedirect.com journal homepage: www.europeanurology.com Incontinence Complete Continence after Botulinum Neurotoxin Type A Injections for Refractory
More informationSdefined as involuntary urine leakage
Transobturator Tape and Female Urinary Incontinence, Follow up and Complication Swapnil Mane*, Sindhu Chandra** Abstract Stress urinary incontinence (SUI) is defined as involuntary urine leakage on exertion.
More informationBotulinum-AToxin Detrusor and Sphincter Injection in Treatment of Overactive Bladder Syndrome: Objective Outcome and Patient Satisfaction
European Urology European Urology 48 (2005) 984 990 Botulinum-AToxin Detrusor and Sphincter Injection in Treatment of Overactive Bladder Syndrome: Objective Outcome and Patient Satisfaction Heinrich Schulte-Baukloh
More informationSurgical management of stress urinary incontinence in Scotland and Wales: A questionnaire study
International Journal of Surgery (2007) 5, 162e166 www.theijs.com Surgical management of stress urinary incontinence in Scotland and Wales: A questionnaire study Min Yu Lim a, *, Mahesh Perera b, Ian Ramsay
More informationOriginal Article. Annals of Rehabilitation Medicine INTRODUCTION
Original Article Ann Rehabil Med 2014;38(3):342-346 pissn: 2234-0645 eissn: 2234-0653 http://dx.doi.org/10.5535/arm.2014.38.3.342 Annals of Rehabilitation Medicine Phasic Changes in Bladder Compliance
More informationInterventional procedures guidance Published: 12 October 2016 nice.org.uk/guidance/ipg566
Single-incision short sling mesh insertion for stress urinary incontinence in women Interventional procedures guidance Published: 12 October 2016 nice.org.uk/guidance/ipg566 Your responsibility This guidance
More informationSupplement. Updated Literature Search for Pharmacologic Treatments for Urgency UI
Supplement. Updated Literature Search for Pharmacologic Treatments for Urgency UI Authors: Tatyana A. Shamliyan, MD, MS Senior Director, Evidence-Based Medicine Quality Assurance Elsevier 1600 JFK Blvd,
More information25-Feb-16 MANAGEMENT OF URINARY INCONTINENCE IN WOMEN.
Female Urinary Incontinence: GP resources MANAGEMENT OF URINARY INCONTINENCE IN WOMEN Dr Marcus Carey 20 February 2016 www.thewomens.org.au Clinical Practice Guidelines GP management of female urinary
More informationThis information is intended as an overview only
This information is intended as an overview only Please refer to the INSTRUCTIONS FOR USE included with this device for indications, contraindications, warnings, precautions and other important information
More informationA Simplified Urinary Incontinence Score for the Evaluation of Treatment Outcomes
Neurourology and Urodynamics 19:127 135 (2000) A Simplified Urinary Incontinence Score for the Evaluation of Treatment Outcomes Asnat Groutz, Jerry G. Blaivas,* and Jarrod E. Rosenthal Weill Medical College,
More informationJohn Laughlin 4 th year Cardiff University Medical Student
John Laughlin 4 th year Cardiff University Medical Student Prolapse/incontinence You need to know: Pelvic floor anatomy in relation to uterovaginal support and continence The classification of uterovaginal
More informationREVIEW OF CAUSES, EVALUATION, AND TREATMENTS URINARY INCONTINENCE 101
REVIEW OF CAUSES, EVALUATION, AND TREATMENTS URINARY INCONTINENCE 101 March 5, 2014 Kevin E Miller, MD Department of Obstetrics and Gynecology University of Kansas School of Medicine- Wichita URINARY INCONTINENCE
More informationManagement of LUTS after TURP and MIT
Management of LUTS after TURP and MIT Hong Sup Kim Konkuk University TURP & MIT TURP : Gold standard MIT TUIP TUNA TUMT HIFU LASER Nd:YAG, ILC, HoLRP, KTP LUTS after TURP and MIT Improved : about 70% Persistent
More informationIncontinence; Lets talk about it. Karanvir Virk M.D. Minimally Invasive and Pelvic Reconstructive Surgery
Incontinence; Lets talk about it Karanvir Virk M.D. Minimally Invasive and Pelvic Reconstructive Surgery Select the most appropriate subtitle for this talk A: Bladders gone wild! B: There s no such thing
More informationEfficacy and safety of a readjustable midurethral sling (Remeex system) for stress urinary incontinence with female voiding dysfunction
Original Article - Female Urology pissn 2466-0493 eissn 2466-054X Efficacy and safety of a readjustable midurethral sling (Remeex system) for stress urinary incontinence with female voiding dysfunction
More informationA Simplified Technique for Botulinum Toxin Injections in Children With Neurogenic Bladder
A Simplified Technique for Botulinum Toxin Injections in Children With Neurogenic Bladder Maria Paola Pascali, Giovanni Mosiello,* Armando Marciano, Maria Luisa Capitanucci, Antonio Maria Zaccara and Mario
More informationSummary. Neuro-urodynamics. The bladder cycle. and voiding. 14/12/2015. Neural control of the LUT Initial assessment Urodynamics
Neuro-urodynamics Summary Neural control of the LUT Initial assessment Urodynamics Marcus Drake, Bristol Urological Institute SAFETY FIRST; renal failure, dysreflexia, latex allergy SYMPTOMS SECOND; storage,
More informationThe Egyptian Journal of Hospital Medicine (July 2018) Vol. 72 (10), Page
The Egyptian Journal of Hospital Medicine (July 2018) Vol. 72 (10), Page 5351-5355 The Efficacy of Transobturator Tape (TOT) in Treatment of Mixed Urinary Incontinence in Females Amr Mohammed Elsadek Nowier,
More informationUrinary incontinence (UI) affects as many
EXPLORING NEW HORIZONS IN STRESS INCONTINENCE: THE NEUROUROLOGY CONNECTION W. Glenn Hurt, MD* ABSTRACT As many as one-third of women are affected by urinary incontinence, the most common of which being
More informationUrinary Incontinence: Revisited
REVIEW ARTICLE 10.5005/jp-journals-10006-1283 1 Narendra Malhotra, 2 Ruchika Garg, 3 Prabhat Agrawal, 4 Rajani Rawat ABSTRACT Patients usually under-report symptoms of incontinence. Therefore, improved
More informationCompassionate and effective management
IMPACT OF STRESS URINARY INCONTINENCE ON QUALITY OF LIFE * Paul Abrams, MD, FRCS ABSTRACT Evaluating the impact of stress urinary incontinence (SUI) on quality of life (QOL) is of paramount importance,
More informationIncidence and Risk Factors of Postoperative De Novo Voiding Dysfunction following Midurethral Sling Procedures
Incidence and Risk Factors of Postoperative De Novo Voiding Dysfunction following Midurethral Sling Procedures Hoon Ah Jang, Jae Hyun Bae, Jeong Gu Lee From the Department of Urology, College of Medicine,
More informationComparison of midurethral sling outcomes with and without concomitant prolapse repair
Original Article Obstet Gynecol Sci 2014;57(1):50-58 http://dx.doi.org/10.5468/ogs.2014.57.1.50 pissn 2287-8572 eissn 2287-8580 Comparison of midurethral sling outcomes with and without concomitant prolapse
More informationOVERACTIVE BLADDER (OAB)
OVERACTIVE BLADDER (OAB) Ms Taryn Hallam Alana Health Care for Women Women s Health Training Associates OVERACTIVE BLADDER The most misdiagnosed and misunderstood of all the urinary disorders. Problem???
More informationPriorities Forum Statement GUIDANCE
Priorities Forum Statement Number 61 Subject The management of female incontinence Date of decision May 2016 Date refreshed May 2017 Date of review May 2019 Introduction: GUIDANCE Urinary incontinence
More informationManagement, Evaluation, and Treatment of Overactive Bladder and Urinary Incontinence
Management, Evaluation, and Treatment of Overactive Bladder and Urinary Incontinence Arthur Mourtzinos, MD, MBA Co-Vice Chair, Institute of Urology Director, Continence Center Assistant Professor of Urology,
More informationMedical Policy Title: Radiofrequency ARBenefits Approval: 10/19/2011
Medical Policy Title: Radiofrequency ARBenefits Approval: 10/19/2011 Treatment, Urinary Stress Incontinence, Transurethral Effective Date: 01/01/2012 Document: ARB0359 Revision Date: Code(s): 53860 Transurethral
More informationMultiple Sclerosis. Véronique Phé, MD, PhD Pitié-Salpêtrière Academic Hospital Department of Urology Paris 6 University Paris, FRANCE
Queen Square Uro-neurology course, London, UK 20 th -21 st October 2016 Multiple Sclerosis Véronique Phé, MD, PhD Pitié-Salpêtrière Academic Hospital Department of Urology Paris 6 University Paris, FRANCE
More informationUP DATE MANAGEMENT OF URINARY INCONTINENCE IN ADULT
UP DATE MANAGEMENT OF URINARY INCONTINENCE IN ADULT Yunizaf, MD Division of Urogynecology Department of Obstetrics and Gynecology School of Medicine, University of Indonesia/ Dr. Cipto Mangunkusumo Hospital
More informationMedical Review Criteria Invasive Treatment for Urinary Incontinence
Medical Review Criteria Invasive Treatment for Urinary Incontinence Effective Date: December 21, 2016 Subject: Invasive Treatment for Urinary Incontinence Background: Urinary incontinence (the involuntary
More information